Stephen L. Rawlings

Array ( [id] => 9670351 [patent_doc_number] => 20140234215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE' [patent_app_type] => utility [patent_app_number] => 14/266391 [patent_app_country] => US [patent_app_date] => 2014-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 15467 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14266391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735969 [patent_doc_number] => 20140271681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'High Affinity Human Antibodies to Human IL-4 Receptor' [patent_app_type] => utility [patent_app_number] => 14/254369 [patent_app_country] => US [patent_app_date] => 2014-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9577 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14254369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699447 [patent_doc_number] => 20160045594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'DIRECTED IMMUNE STIMULATION' [patent_app_type] => utility [patent_app_number] => 14/780379 [patent_app_country] => US [patent_app_date] => 2014-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 21315 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14780379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919111 [patent_doc_number] => 20140322130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'SPECIFIC BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/226430 [patent_app_country] => US [patent_app_date] => 2014-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 161 [patent_figures_cnt] => 161 [patent_no_of_words] => 85899 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14226430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13093363 [patent_doc_number] => 10066013 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => Anti-PD-1 antibody and use thereof [patent_app_type] => utility [patent_app_number] => 14/392360 [patent_app_country] => US [patent_app_date] => 2014-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 7778 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14392360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771183 [patent_doc_number] => 20140294846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'FUNCTION AND REGULATION OF ADAMTS-1' [patent_app_type] => utility [patent_app_number] => 14/183341 [patent_app_country] => US [patent_app_date] => 2014-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 22497 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14183341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771183 [patent_doc_number] => 20140294846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'FUNCTION AND REGULATION OF ADAMTS-1' [patent_app_type] => utility [patent_app_number] => 14/183341 [patent_app_country] => US [patent_app_date] => 2014-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 22497 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14183341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10712707 [patent_doc_number] => 20160058854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'CANCER VACCINES AND VACCINATION METHODS' [patent_app_type] => utility [patent_app_number] => 14/766685 [patent_app_country] => US [patent_app_date] => 2014-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26936 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14766685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656185 [patent_doc_number] => 20160002330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'CETUXIMAB WITH MODIFIED GLYCOSYLATION AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/767089 [patent_app_country] => US [patent_app_date] => 2014-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 12874 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14767089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10470164 [patent_doc_number] => 20150355181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'METHODS AND COMPOSITIONS FOR HUMAN EPIDIDYMIS PROTEIN-4 (HE4)' [patent_app_type] => utility [patent_app_number] => 14/763202 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 8386 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14763202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10692427 [patent_doc_number] => 20160038573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'SELECTIVE CELL-DEATH-INDUCING BINARY ENZYME SYSTEM' [patent_app_type] => utility [patent_app_number] => 14/761632 [patent_app_country] => US [patent_app_date] => 2014-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4052 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14761632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919182 [patent_doc_number] => 20140322202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'TREATMENT WITH ANTI ErbB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/141190 [patent_app_country] => US [patent_app_date] => 2013-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15823 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14141190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459551 [patent_doc_number] => 20150344567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/654376 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 18832 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14654376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15515137 [patent_doc_number] => 10564150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Cell mediated immune response assay [patent_app_type] => utility [patent_app_number] => 14/758189 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19504 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 674 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14758189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9449999 [patent_doc_number] => 20140121169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis' [patent_app_type] => utility [patent_app_number] => 14/137256 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9075 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14137256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11809852 [patent_doc_number] => 09714413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-25 [patent_title] => 'Co-differentiation of monocytes from allogeneic donors' [patent_app_type] => utility [patent_app_number] => 14/653184 [patent_app_country] => US [patent_app_date] => 2013-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 42 [patent_no_of_words] => 10295 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14653184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12199719 [patent_doc_number] => 09902775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Anti-blood dendritic cell antigen 2 antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/649297 [patent_app_country] => US [patent_app_date] => 2013-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 95 [patent_no_of_words] => 61347 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14649297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422617 [patent_doc_number] => 20150307628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'CH3 DOMAIN VARIANT PAIR INDUCING FORMATION OF HETERODIMER OF HEAVY CHAIN CONSTANT REGION OF ANTIBODY AT HIGH EFFICIENCY, METHOD FOR PREPARING SAME, AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/647480 [patent_app_country] => US [patent_app_date] => 2013-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 17478 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14647480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9568664 [patent_doc_number] => 20140186377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/090664 [patent_app_country] => US [patent_app_date] => 2013-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 55494 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14090664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9383420 [patent_doc_number] => 20140086901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-27 [patent_title] => 'Inhibition of Post-Radiation Tumor Growth' [patent_app_type] => utility [patent_app_number] => 14/089141 [patent_app_country] => US [patent_app_date] => 2013-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 13749 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14089141 [rel_patent_id] =>[rel_patent_doc_number] =>)